Kezar Life Sciences, Inc.

This study tested whether adding an investigational drug called zetomipzomib to standard steroid therapy could better control autoimmune hepatitis. It involved 24 adults whose liver disease was still active despite standard care. Participants received weekly injections of either …

This early-stage study tested a new drug called KZR-616 for people with lupus, including those with kidney inflammation (lupus nephritis). The drug was given as a weekly injection under the skin for 13 or 24 weeks, in addition to patients' standard lupus medications. The main goa…

This study tested whether a weekly injection called KZR-616 could safely improve muscle strength and overall disease activity in adults with active polymyositis or dermatomyositis. Twenty-five participants received either the drug or a placebo for 16 weeks, then switched to the o…

This study followed patients with polymyositis or dermatomyositis who had previously participated in a related trial. It aimed to assess the long-term safety and effectiveness of weekly KZR-616 injections over up to 96 weeks of treatment. The goal was to see if the drug could hel…